Back to Results

Codexis Inc (CDXS)

Codexis, Inc. is a healthcare company listed on NASDAQ as common stock. The company develops enzyme-based technology for therapeutics manufacturing, centered on its CodeEvolver platform, which is used to discover, develop, improve, and commercialize novel enzymes. It also works on the ECO Synthesis manufacturing platform, designed to support scaled RNAi therapeutics production through an enzymatic process. Codexis conducts business across North America, Europe, the Middle East, Africa, Asia-Pacific, and China. The company has license agreements with Aldevron LLC and Pfizer Inc. Founded in 2002, Codexis is headquartered in Redwood City, California.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-CDXS
$1.73
26.8% Upside
Undervalued
$6.33
364.0% Upside
Bargain
Fair
0.0%
October 29, 2026
4.5x
1.9x
146.7 M
161.9 M
32.4%
75.2%
-6.0
39.6%
Valuation • Fair Value

Codexis Inc (NASDAQ-CDXS) Fair Value by Valuation Model

Review the available estimates for Codexis Inc (NASDAQ-CDXS), including DCF Fair Value, EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$1.73

Estimated upside of 26.8% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$2.08

Discounted cash flow valuation reference.

EPV Fair Value

$0.97

Earnings power value estimate.

Comps Fair Value

$1.68

Comparable-company valuation reference.

Analyst Price Target

$6.33

Analysts imply upside of 364.0%.

How to read these valuation models

Use the 6 available valuation references for Codexis Inc (NASDAQ-CDXS) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Codexis Inc (NASDAQ-CDXS)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

77.679 M

Current operating scale indicator.

Revenue Forecast

73.846 M

Forward revenue estimate.

EBITDA

-19.047 M

Current operating profitability reference.

EBITDA Forecast

-17.6 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Codexis Inc (NASDAQ-CDXS) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Codexis Inc (NASDAQ-CDXS)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

-4.12

No elevated caution signal from this screen.

Altman Z-Score

-6.0

Lower score that deserves closer risk review.

FCF / Net Income

39.6%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Codexis Inc (NASDAQ-CDXS). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Codexis Inc (NASDAQ-CDXS)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

October 29, 2026

Days to Earnings

42

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Codexis Inc (NASDAQ-CDXS), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Codexis Inc (NASDAQ-CDXS) Stock Forecast & Technical Outlook

Review Codexis Inc (NASDAQ-CDXS) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Codexis Inc (NASDAQ-CDXS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Codexis Inc (NASDAQ-CDXS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Codexis Inc (NASDAQ-CDXS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Codexis Inc (NASDAQ-CDXS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Codexis Inc (NASDAQ-CDXS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Codexis Inc (NASDAQ-CDXS)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Buy

Based on the available recommendation mix, Codexis Inc (NASDAQ-CDXS) has a Buy consensus, with 4 buy, 2 hold and 0 sell recommendations in the current data set.

Buy 4
Hold 2
Sell 0
FAQ • Fast Investor Answers

Codexis Inc (NASDAQ-CDXS) Stock FAQ

Data-supported answers about Codexis Inc (NASDAQ-CDXS), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$1.73
Estimated upside 26.8%
Valuation Rating
Undervalued
Estimated upside of 26.8%
Analyst Target
$6.33
Implied upside 364.0%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Codexis Inc (NASDAQ-CDXS) is $1.73. This implies an estimated upside of 26.8% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 26.8% versus the current market price.

The available analyst price target for Codexis Inc (NASDAQ-CDXS) is $6.33. The analyst target implies estimated upside of 364.0%.

The current financial health read for Codexis Inc (NASDAQ-CDXS) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Codexis Inc (NASDAQ-CDXS) is October 29, 2026.

The latest available data indicates no current dividend yield for Codexis Inc (NASDAQ-CDXS).

The current market capitalization listed for Codexis Inc is 146.7 M.

The current enterprise value listed for Codexis Inc is 161.9 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Codexis Inc is NASDAQ-CDXS, and the stock is listed on NASDAQ.

Codexis Inc (NASDAQ-CDXS) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Codexis Inc is 32.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Codexis Inc is 75.2%. Free float helps investors understand how much of the share base is available for public trading.

Similar Life Sciences Tools & Services Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

TMO NYSE Thermo Fisher Scientific Inc Fair Value Fair Market Cap 239.8 B
DHR NYSE Danaher Corporation Fair Value Fair Market Cap 146.5 B
IQV NYSE IQVIA Holdings Inc Fair Value Fair Market Cap 44.248 B
A NYSE Agilent Technologies Inc Fair Value Fair Market Cap 43.33 B
WAT NYSE Waters Corporation Fair Value Overvalued Market Cap 41.131 B
ILMN NASDAQ Illumina Inc Fair Value Overvalued Market Cap 34.568 B
MTD NYSE Mettler-Toledo International Inc Fair Value Fair Market Cap 27.624 B
WST NYSE West Pharmaceutical Services Inc Fair Value Fair Market Cap 25.477 B
MEDP NASDAQ Medpace Holdings Inc Fair Value Fair Market Cap 17.206 B
RVTY NYSE Revvity Inc Fair Value Overvalued Market Cap 16.261 B
ICLR NASDAQ ICON PLC Fair Value Fair Market Cap 13.42 B
CRL NYSE Charles River Laboratories Fair Value Overvalued Market Cap 13.052 B
TEM NASDAQ Tempus AI Inc Fair Value Overvalued Market Cap 12.625 B
TECH NASDAQ Bio-Techne Corp Fair Value Fair Market Cap 11.343 B
AVTR NYSE Avantor Inc Fair Value Fair Market Cap 10.558 B
BIOB NYSE Bio-Rad Laboratories B Fair Value Fair Market Cap 10.064 B
BIO NYSE Bio-Rad Laboratories Inc Fair Value Fair Market Cap 10.064 B
RGEN NASDAQ Repligen Corporation Fair Value Overvalued Market Cap 9.758 B
TXG NASDAQ 10X Genomics Inc Fair Value Overvalued Market Cap 9.47 B
BRKR NASDAQ Bruker Corporation Fair Value Overvalued Market Cap 9.244 B